Chapter 2 Progesterone Receptor Action in Leiomyoma and Endometrial Cancer

Progress in Molecular Biology and Translational Science

Volumn 87, Issue C, 2009, Pages 53-85

  Kim, J Julie ^a   Sefton, Elizabeth C ^a   Bulun, Serdar E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGESTERONE RECEPTOR;

CHEMISTRY; ENDOMETRIUM; ENDOMETRIUM TUMOR; FEMALE; HUMAN; LEIOMYOMA; METABOLISM; MYOMETRIUM; PATHOLOGY; REVIEW;

ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; LEIOMYOMA; MYOMETRIUM; RECEPTORS, PROGESTERONE;

EID: 77957046782     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-1173(09)87002-6     Document Type: Review

References (194)

1. Kurita T., and Nakamura H. Embryology and anatomy of the uterus. In: Aplin J., Fazleabas S., Glasser S., and Giudice L. (Eds). The Endometrium, Molecular, Cellular, and Clinical Perspectives. 2nd ed (2007), Harwood Academic Publishers
2. Norman A.W., and Litwack G. Hormones (1987), Academic Press, Orlando, FL
3. Clarke C.L., and Sutherland R.L. Progestin regulation of cellular proliferation. Endocr Rev 11 (1990) 266-301
4. Dockery P., Li T.C., Rogers A.W., Cooke I.D., and Lenton E.A. The ultrastructure of the glandular epithelium in the timed endometrial biopsy. Hum Reprod 3 (1988) 826 34
5. Wynn R.M. Ultrastructural development of the human decidua. Am J Obstet Gynecol 118 (1974) 652 70
6. Gellersen B., and Brosens J. Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair. J Endocrinol 178 (2003) 357 72
7. de Ziegler D., Bulletti C., Fanchin R., Epiney M., and Brioschi P.A. Contractility of the nonpregnant uterus: the follicular phase. Ann N Y Acad Sci 943 (2001) 172 84
8. Boroditsky R.S., Reyes F.I., Winter J.S., and Faiman C. Maternal serum estrogen and progesterone concentrations preceding normal labor. Obstet Gynecol 51 (1978) 686 91
9. Tulchinsky D., Hobel C.J., Yeager E., and Marshall J.R. Plama estradiol, estriol, and progesterone in human pregnancy. II. Clinical applications in Rh-isoimmunization disease. Am J Obstet Gynecol 113 (1972) 766 70
10. Walsh S.W., Stanczyk F.Z., and Novy M.J. Daily hormonal changes in the maternal, fetal, and amniotic fluid compartments before parturition in a primate species. J Clin Endocrinol Metab 58 (1984) 629 39
11. Haluska G.J., Cook M.J., and Novy M.J. Inhibition and augmentation of progesterone production during pregnancy: effects on parturition in rhesus monkeys. Am J Obstet Gynecol 176 (1997) 682 91
12. Selinger M., Mackenzie I.Z., Gillmer M.D., Phipps S.L., and Ferguson J. Progesterone inhibition in mid-trimester termination of pregnancy: physiological and clinical effects. Br J Obstet Gynaecol 94 (1987) 1218 22
13. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835 9
14. Robinson-Rechavi M., Escriva Garcia H., and Laudet V. The nuclear receptor superfamily. J Cell Sci 116 (2003) 585 6
15. Gronemeyer H., Meyer M.E., Bocquel M.T., Kastner P., Turcotte B., and Chambon P. Progestin receptors: isoforms and antihormone action. J Steroid Biochem Mol Biol 40 (1991) 271 8
16. Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H., et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9 (1990) 1603 14
17. Lessey B.A., Alexander P.S., and Horwitz K.B. The subunit structure of human breast cancer progesterone receptors: characterization by chromatography and photoaffinity labeling. Endocrinology 112 (1983) 1267 74
18. McDonnell D.P., Shahbaz M.M., Vegeto E., and Goldman M.E. The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. J Steroid Biochem Mol Biol 48 (1994) 425 32
19. Tetel M.J., Giangrande P.H., Leonhardt S.A., McDonnell D.P., and Edwards D.P. Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. Mol Endocrinol 13 (1999) 910 24
20. Tung L., Abdel-Hafiz H., Shen T., Harvell D.M., Nitao L.K., Richer J.K., et al. Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol 20 (2006) 2656 70
21. Tung L., Mohamed M.K., Hoeffler J.P., Takimoto G.S., and Horwitz K.B. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7 (1993) 1256 65
22. Vegeto E., Shahbaz M.M., Wen D.X., Goldman M.E., O'Malley B.W., and McDonnell D.P. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7 (1993) 1244 55
23. Chi T., Lieberman P., Ellwood K., and Carey M. A general mechanism for transcriptional synergy by eukaryotic activators. Nature 377 (1995) 254 7
24. Giangrande P.H., Kimbrel E.A., Edwards D.P., and McDonnell D.P. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 20 (2000) 3102 15
25. Wagner B.L., Norris J.D., Knotts T.A., Weigel N.L., and McDonnell D.P. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 18 (1998) 1369 78
26. Ellwood K., Huang W., Johnson R., and Carey M. Multiple layers of cooperativity regulate enhanceosome-responsive RNA polymerase II transcription complex assembly. Mol Cell Biol 19 (1999) 2613 23
27. Miner J.N., and Yamamoto K.R. The basic region of AP-1 specifies glucocorticoid receptor activity at a composite response element. Genes Dev 6 (1992) 2491 501
28. Prefontaine G.G., Lemieux M.E., Giffin W., Schild-Poulter C., Pope L., LaCasse E., et al. Recruitment of octamer transcription factors to DNA by glucocorticoid receptor. Mol Cell Biol 18 (1998) 3416 30
29. Schule R., Muller M., Kaltschmidt C., and Renkawitz R. Many transcription factors interact synergistically with steroid receptors. Science 242 (1988) 1418 20
30. O'Malley B.W. Coregulators: from whence came these "master genes". Mol Endocrinol 21 (2007) 1009 13
31. Li X., Wong J., Tsai S.Y., Tsai M.J., and O'Malley B.W. Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 23 (2003) 3763 73
32. Xu J., Qiu Y., DeMayo F.J., Tsai S.Y., Tsai M.J., and O'Malley B.W. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279 (1998) 1922 5
33. Gehin M., Mark M., Dennefeld C., Dierich A., Gronemeyer H., and Chambon P. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol Cell Biol 22 (2002) 5923 37
34. Jeong J.W., Lee K.Y., Han S.J., Aronow B.J., Lydon J.P., O'Malley B.W., et al. The p160 steroid receptor coactivator 2, SRC-2, regulates murine endometrial function and regulates progesterone-independent and -dependent gene expression. Endocrinology 148 (2007) 4238 50
35. Mukherjee A., Soyal S.M., Fernandez-Valdivia R., Gehin M., Chambon P., Demayo F.J., et al. Steroid receptor coactivator 2 is critical for progesterone-dependent uterine function and mammary morphogenesis in the mouse. Mol Cell Biol 26 (2006) 6571 83
36. Bamberger A.M., Bamberger C.M., Gellersen B., and Schulte H.M. Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc Natl Acad Sci USA 93 (1996) 6169 74
37. Gronemeyer H. Transcription activation by estrogen and progesterone receptors. Annu Rev Genet 25 (1991) 89-123
38. Kalkhoven E., Wissink S., van der Saag P.T., and van der Burg B. Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor. J Biol Chem 271 (1996) 6217 24
39. Kim J.J., Buzzio O.L., Li S., and Lu Z. Role of FOXO1A in the regulation of insulin-like growth factor-binding protein-1 in human endometrial cells: interaction with progesterone receptor. Biol Reprod 73 (2005) 833 9
40. Takano M., Lu Z., Goto T., Fusi L., Higham J., Francis J., et al. Transcriptional cross talk between the forkhead transcription factor forkhead box O1A and the progesterone receptor coordinates cell cycle regulation and differentiation in human endometrial stromal cells. Mol Endocrinol 21 (2007) 2334 49
41. Li X., and O'Malley B.W. Unfolding the action of progesterone receptors. J Biol Chem 278 (2003) 39261 4
42. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 (2005) 33-43
43. Schuur E.R., Loktev A.V., Sharma M., Sun Z., Roth R.A., and Weigel R.J. Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family. J Biol Chem 276 (2001) 33554 60
44. Zhao H.H., Herrera R.E., Coronado-Heinsohn E., Yang M.C., Ludes-Meyers J.H., Seybold-Tilson K.J., et al. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem 276 (2001) 27907 12
45. Mulac-Jericevic B., Lydon J.P., DeMayo F.J., and Conneely O.M. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 100 (2003) 9744 9
46. Mulac-Jericevic B., Mullinax R.A., DeMayo F.J., Lydon J.P., and Conneely O.M. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289 (2000) 1751 4
47. Condon J.C., Hardy D.B., Kovaric K., and Mendelson C.R. Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-kappaB may contribute to the onset of labor through inhibition of PR function. Mol Endocrinol 20 (2006) 764 75
48. Garcia E., Bouchard P., De Brux J., Berdah J., Frydman R., Schaison G., et al. Use of immunocytochemistry of progesterone and estrogen receptors for endometrial dating. J Clin Endocrinol Metab 67 (1988) 80 7
49. Mylonas I., Jeschke U., Shabani N., Kuhn C., Kunze S., Dian D., et al. Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol Histopathol 22 (2007) 169 76
50. Snijders M.P., de Goeij A.F., Debets-Te Baerts M.J., Rousch M.J., Koudstaal J., and Bosman F.T. Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. J Reprod Fertil 94 (1992) 363 71
51. Nisolle M., Gillerot S., Casanas-Roux F., Squifflet J., Berliere M., and Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 14 (1999) 2844 50
52. Vienonen A., Miettinen S., Blauer M., Martikainen P.M., Tomas E., Heinonen P.K., et al. Expression of nuclear receptors and cofactors in human endometrium and myometrium. J Soc Gynecol Investig 11 (2004) 104 12
53. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
54. Clement P.B., and Young R.H. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 9 (2002) 145 84
55. Creasman W.T., and Eddy G.L. Recent advances in endometrial cancer. Semin Surg Oncol 6 (1990) 339 42
56. Judd H.L., Judd G.E., Lucas W.E., and Yen S.S. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 39 (1974) 1020 4
57. Kirschner M.A., Schneider G., Ertel N.H., and Worton E. Obesity, androgens, estrogens, and cancer risk. Cancer Res 42 (1982) 3281s 5s
58. Munstedt K., Grant P., Woenckhaus J., Roth G., and Tinneberg H.R. Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg Oncol 2 (2004) 24
59. Ryan A.J., Susil B., Jobling T.W., and Oehler M.K. Endometrial cancer. Cell Tissue Res 322 (2005) 53-61
60. Cohen C.J., and Rahaman J. Endometrial cancer. Management of high risk and recurrence including the tamoxifen controversy. Cancer 76 (1995) 2044 52
61. Jadoul P., and Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 80 (2003) 1315 24
62. Randall T.C., and Kurman R.J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90 (1997) 434 40
63. Gal D., Edman C.D., Vellios F., and Forney J.P. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol 146 (1983) 316 22
64. Ferenczy A., and Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 160 (1989) 126 31
65. Lai C.H., and Huang H.J. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 18 (2006) 29-34
66. Martin-Hirsch P.L., Lilford R.J., and Jarvis G.J. Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials. Eur J Obstet Gynecol Reprod Biol 65 (1996) 201 7
67. Benshushan A. Endometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatment. Eur J Obstet Gynecol Reprod Biol 117 (2004) 132 7
68. Crissman J.D., Azoury R.S., Barnes A.E., and Schellhas H.F. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 57 (1981) 699-704
69. Gallup D.G., and Stock R.J. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 64 (1984) 417 20
70. Lowe M.P., Bender D., Sood A.K., Davis W., Syrop C.H., and Sorosky J.I. Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction. Fertil Steril 77 (2002) 188 9
71. Chiva L., Lapuente F., Gonzalez-Cortijo L., Carballo N., Garcia J.F., Rojo A., et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol 111 (2008) S101 4
72. Ushijima K., Yahata H., Yoshikawa H., Konishi I., Yasugi T., Saito T., et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25 (2007) 2798 803
73. Leslie K.K., Stein M.P., Kumar N.S., Dai D., Stephens J., Wandinger-Ness A., et al. Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol 96 (2005) 32-41
74. Smid-Koopman E., Blok L.J., Kuhne L.C., Burger C.W., Helmerhorst T.J., Brinkmann A.O., et al. Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines. J Soc Gynecol Investig 10 (2003) 49-57
75. Hanekamp E.E., Kuhne L.M., Grootegoed J.A., Burger C.W., and Blok L.J. Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice. Endocr Relat Cancer 11 (2004) 831 41
76. Fujimoto J., Ichigo S., Hori M., Nishigaki M., and Tamaya T. Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumour Biol 16 (1995) 254 60
77. Arnett-Mansfield R.L., deFazio A., Wain G.V., Jaworski R.C., Byth K., Mote P.A., et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61 (2001) 4576 82
78. Kumar N.S., Richer J., Owen G., Litman E., Horwitz K.B., and Leslie K.K. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res 58 (1998) 1860 5
79. Dai D., Wolf D.M., Litman E.S., White M.J., and Leslie K.K. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 62 (2002) 881 6
80. Ueda M., Fujii H., Yoshizawa K., Abe F., and Ueki M. Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro. Jpn J Cancer Res 87 (1996) 524 33
81. Saito T., Mizumoto H., Tanaka R., Satohisa S., Adachi K., Horie M., et al. Overexpressed progesterone receptor form B inhibit invasive activity suppressing matrix metalloproteinases in endometrial carcinoma cells. Cancer Lett 209 (2004) 237 43
82. Di Nezza L.A., Jobling T., and Salamonsen L.A. Progestin suppresses matrix metalloproteinase production in endometrial cancer. Gynecol Oncol 89 (2003) 325 33
83. Jaffe R.C., Ferguson-Gottschall S.D., Gao W., Beam C., and Fazleabas A.T. Histone deacetylase inhibition and progesterone act synergistically to stimulate baboon glycodelin gene expression. J Mol Endocrinol 38 (2007) 401 7
84. Uchida H., Maruyama T., Nagashima T., Asada H., and Yoshimura Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 146 (2005) 5365 73
85. Uchida H., Maruyama T., Ono M., Ohta K., Kajitani T., Masuda H., et al. Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 148 (2007) 896-902
86. Ohta K., Maruyama T., Uchida H., Ono M., Nagashima T., Arase T., et al. Glycodelin blocks progression to S phase and inhibits cell growth: a possible progesterone-induced regulator for endometrial epithelial cell growth. Mol Hum Reprod 14 (2008) 17-22
87. Ward E.C., Hoekstra A.V., Blok L.J., Hanifi-Moghaddam P., Lurain J.R., Singh D.K., et al. The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology 149 (2008) 1942 50
88. Goto T., Takano M., Albergaria A., Briese J., Pomeranz K.M., Cloke B., et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 27 (2008) 9-19
89. Shiozawa T., Nikaido T., Nakayama K., Lu X., and Fujii S. Involvement of cyclin-dependent kinase inhibitor p27Kip1 in growth inhibition of endometrium in the secretory phase and of hyperplastic endometrium treated with progesterone. Mol Hum Reprod 4 (1998) 899-905
90. Watanabe J., Watanabe K., Jobo T., Kamata Y., Kawaguchi M., Imai M., et al. Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma. Int J Gynecol Cancer 16 Suppl 1 (2006) 452 7
91. Paulssen R.H., Moe B., Gronaas H., and Orbo A. Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids 73 (2008) 116 28
92. Hanekamp E.E., Kuhne E.C., Smid-Koopman E., de Ruiter P.E., Chadha-Ajwani S., Brinkmann A.O., et al. Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Eur J Cancer 38 Suppl 6 (2002) S71 2
93. Davies S., Dai D., Wolf D.M., and Leslie K.K. Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells. J Soc Gynecol Investig 11 (2004) 494 9
94. Vereide A.B., Kaino T., Sager G., and Orbo A. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 97 (2005) 740 50
95. Dai D., Kumar N.S., Wolf D.M., and Leslie K.K. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation. Am J Obstet Gynecol 184 (2001) 790 7
96. Dai D., Litman E.S., Schonteich E., and Leslie K.K. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Mol Biol 87 (2003) 123 31
97. Davies S., Dai D., Feldman I., Pickett G., and Leslie K.K. Identification of a novel mechanism of NF-kappaB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2. Gynecol Oncol 94 (2004) 463 70
98. Gao J., Mazella J., Seppala M., and Tseng L. Ligand activated hPR modulates the glycodelin promoter activity through the Sp1 sites in human endometrial adenocarcinoma cells. Mol Cell Endocrinol 176 (2001) 97-102
99. Salih S.M., Salama S.A., Jamaluddin M., Fadl A.A., Blok L.J., Burger C.W., et al. Progesterone-mediated regulation of catechol-O-methyl transferase expression in endometrial cancer cells. Reprod Sci 15 (2008) 210 20
100. Zhang X.L., Zhang D., Michel F.J., Blum J.L., Simmen F.A., and Simmen R.C. Selective interactions of Kruppel-like factor 9/basic transcription element-binding protein with progesterone receptor isoforms A and B determine transcriptional activity of progesterone-responsive genes in endometrial epithelial cells. J Biol Chem 278 (2003) 21474 82
101. Cramer S.F., and Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 94 (1990) 435 8
102. Day Baird D., Dunson D.B., Hill M.C., Cousins D., and Schectman J.M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188 (2003) 100 7
103. Farquhar C.M., and Steiner C.A. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 99 (2002) 229 34
104. Parker W.H. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 87 (2007) 725 36
105. Williams A.J., Powell W.L., Collins T., and Morton C.C. HMGI(Y) expression in human uterine leiomyomata. Involvement of another high-mobility group architectural factor in a benign neoplasm. Am J Pathol 150 (1997) 911 8
106. Cermik D., Arici A., and Taylor H.S. Coordinated regulation of HOX gene expression in myometrium and uterine leiomyoma. Fertil Steril 78 (2002) 979 84
107. Brandon D.D., Bethea C.L., Strawn E.Y., Novy M.J., Burry K.A., Harrington M.S., et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 169 (1993) 78-85
108. Englund K., Blanck A., Gustavsson I., Lundkvist U., Sjoblom P., Norgren A., et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 83 (1998) 4092 6
109. Kawaguchi K., Fujii S., Konishi I., Nanbu Y., Nonogaki H., and Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 160 (1989) 637 41
110. Tiltman A.J. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 4 (1985) 89-96
111. Harrison-Woolrych M.L., Charnock-Jones D.S., and Smith S.K. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab 78 (1994) 1179 84
112. Maruo T., Matsuo H., Samoto T., Shimomura Y., Kurachi O., Gao Z., et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 65 (2000) 585 92
113. Kurachi O., Matsuo H., Samoto T., and Maruo T. Tumor necrosis factor-alpha expression in human uterine leiomyoma and its down-regulation by progesterone. J Clin Endocrinol Metab 86 (2001) 2275 80
114. Matsuo H., Kurachi O., Shimomura Y., Samoto T., and Maruo T. Molecular bases for the actions of ovarian sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma. Oncology 57 Suppl 2 (1999) 49-58
115. Matsuo H., Maruo T., and Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82 (1997) 293 9
116. Maruo T., Matsuo H., Shimomura Y., Kurachi O., Gao Z., Nakago S., et al. Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids 68 (2003) 817 24
117. Carr B.R., Marshburn P.B., Weatherall P.T., Bradshaw K.D., Breslau N.A., Byrd W., et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 76 (1993) 1217 23
118. Friedman A.J., Daly M., Juneau-Norcross M., Rein M.S., Fine C., Gleason R., et al. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 76 (1993) 1439 45
119. Rosati P., Exacoustos C., and Mancuso S. Longitudinal evaluation of uterine myoma growth during pregnancy. A sonographic study. J Ultrasound Med 11 (1992) 511 5
120. Aharoni A., Reiter A., Golan D., Paltiely Y., and Sharf M. Patterns of growth of uterine leiomyomas during pregnancy. A prospective longitudinal study. Br J Obstet Gynaecol 95 (1988) 510 3
121. Neiger R., Sonek J.D., Croom C.S., and Ventolini G. Pregnancy-related changes in the size of uterine leiomyomas. J Reprod Med 51 (2006) 671 4
122. Hammoud A.O., Asaad R., Berman J., Treadwell M.C., Blackwell S., and Diamond M.P. Volume change of uterine myomas during pregnancy: do myomas really grow?. J Minim Invasive Gynecol 13 (2006) 386 90
123. Murphy A.A., Kettel L.M., Morales A.J., Roberts V.J., and Yen S.S. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 76 (1993) 513 7
124. Murphy A.A., Morales A.J., Kettel L.M., and Yen S.S. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 64 (1995) 187 90
125. Eisinger S.H., Meldrum S., Fiscella K., le Roux H.D., and Guzick D.S. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 101 (2003) 243 50
126. Murphy L.L., and Mahesh V.B. Selective release of follicle-stimulating hormone and luteinizing hormone by 5à-dihydroprogesterone and 3à,5à- tetrahydroprogesterone in pregnant mare's serum gonadotropin- primed immature rats exposed to constant light. Biol Reprod 32 (1985) 795-803
127. Williams A.R., Critchley H.O., Osei J., Ingamells S., Cameron I.T., Han C., et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod (2007)
128. Steinauer J., Pritts E.A., Jackson R., and Jacoby A.F. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 103 (2004) 1331 6
129. Chwalisz K., Larsen L., Mattia-Goldberg C., Edmonds A., Elger W., and Winkel C.A. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 87 (2007) 1399 412
130. Eisinger S.H., Bonfiglio T., Fiscella K., Meldrum S., and Guzick D.S. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 12 (2005) 227 33
131. Fiscella K., Eisinger S.H., Meldrum S., Feng C., Fisher S.G., and Guzick D.S. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 108 (2006) 1381 7
132. Madauss K.P., Grygielko E.T., Deng S.J., Sulpizio A.C., Stanley T.B., Wu C., et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol 21 (2007) 1066 81
133. Chen W., Ohara N., Wang J., Xu Q., Liu J., Morikawa A., et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 91 (2006) 1296 304
134. Wang J., Ohara N., Wang Z., Chen W., Morikawa A., Sasaki H., et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod 21 (2006) 1869 77
135. Sasaki H., Ohara N., Xu Q., Wang J., DeManno D.A., Chwalisz K., et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 92 (2007) 616 23
136. Stewart E.A., Austin D.J., Jain P., Penglase M.D., and Nowak R.A. RU486 suppresses prolactin production in explant cultures of leiomyoma and myometrium. Fertil Steril 65 (1996) 1119 24
137. Hyder S.M., Huang J.C., Nawaz Z., Boettger-Tong H., Makela S., Chiappetta C., et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect 108 Suppl 5 (2000) 785 90
138. Wang H., and Jin J. [Effects of mifepristone on estrogen and progestin receptors in human uterine leiomyoma]. Zhonghua Fu Chan Ke Za Zhi 35 (2000) 79-81
139. Chegini N., Ma C., Tang X.M., and Williams R.S. Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod 8 (2002) 1071 8
140. Jeng Y.J., Suarez V.R., Izban M.G., Wang H.Q., and Soloff M.S. Progesterone-induced sphingosine kinase-1 expression in the rat uterus during pregnancy and signaling consequences. Am J Physiol Endocrinol Metab 292 (2007) E1110 21
141. Kettel L.M., Murphy A.A., Morales A.J., and Yen S.S. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 9 Suppl 1 (1994) 116 20
142. Murphy A.A., and Castellano P.Z. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. Curr Opin Obstet Gynecol 6 (1994) 269 78
143. Ramachandran S., Song M.Q., Lowe E., Dominguez C.E., Parthasarathy S., and Murphy A.A. RU486 inhibits expression of lysophosphatidic acid induced glycodelin. Am J Obstet Gynecol 192 (2005) 1285 93 discussion 1293-84
144. Kayisli U.A., Berkkanoglu M., Kizilay G., Senturk L., and Arici A. Expression of proliferative and preapoptotic molecules in human myometrium and leiomyoma throughout the menstrual cycle. Reprod Sci 14 (2007) 678 86
145. Shimomura Y., Matsuo H., Samoto T., and Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 83 (1998) 2192 8
146. Ohara N., Morikawa A., Chen W., Wang J., DeManno D.A., Chwalisz K., et al. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod Sci 14 (2007) 20 7
147. Kovacs K.A., Lengyel F., Kornyei J.L., Vertes Z., Szabo I., Sumegi B., et al. Differential expression of Akt/protein kinase B, Bcl-2 and Bax proteins in human leiomyoma and myometrium. J Steroid Biochem Mol Biol 87 (2003) 233 40
148. Wu X., Blanck A., Olovsson M., Henriksen R., and Lindblom B. Expression of Bcl-2, Bcl-x, Mcl-1, Bax and Bak in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause. J Steroid Biochem Mol Biol 80 (2002) 77-83
149. Yin P., Lin Z., Cheng Y.H., Marsh E.E., Utsunomiya H., Ishikawa H., et al. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J Clin Endocrinol Metab 92 (2007) 4459 66
150. Hassan M.H., Salama S.A., Arafa H.M., Hamada F.M., and Al-Hendy A. Adenovirus-mediated delivery of a dominant-negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J Clin Endocrinol Metab 92 (2007) 3949 57
151. Stewart E.A., Friedman A.J., Peck K., and Nowak R.A. Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab 79 (1994) 900 6
152. Dou Q., Tarnuzzer R.W., Williams R.S., Schultz G.S., and Chegini N. Differential expression of matrix metalloproteinases and their tissue inhibitors in leiomyomata: a mechanism for gonadotrophin releasing hormone agonist-induced tumour regression. Mol Hum Reprod 3 (1997) 1005 14
153. Levens E., Luo X., Ding L., Williams R.S., and Chegini N. Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-beta through Smad and MAPK-mediated signalling. Mol Hum Reprod 11 (2005) 489 94
154. Morikawa A., Ohara N., Xu Q., Nakabayashi K., DeManno D.A., Chwalisz K., et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod 23 (2008) 944 51
155. Marsh E.E., Lin Z., Yin P., Milad M., Chakravarti D., and Bulun S.E. Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium. Fertil Steril 89 (2008) 1771 6
156. Wang T., Zhang X., Obijuru L., Laser J., Aris V., Lee P., et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 46 (2007) 336 47
157. Pan Q., Luo X., and Chegini N. Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med 12 (2008) 227 40
158. Rossi M.J., Chegini N., and Masterson B.J. Presence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology 130 (1992) 1716 27
159. Yeh J., Rein M., and Nowak R. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata. Fertil Steril 56 (1991) 997 1000
160. Chandrasekhar Y., Heiner J., Osuamkpe C., and Nagamani M. Insulin-like growth factor I and II binding in human myometrium and leiomyomas. Am J Obstet Gynecol 166 (1992) 64 9
161. Yu L., Saile K., Swartz C.D., He H., Zheng X., Kissling G.E., et al. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med 14 (2008) 264 75
162. Gao Z., Matsuo H., Wang Y., Nakago S., and Maruo T. Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 86 (2001) 5593 9
163. Strawn Jr. E.Y., Novy M.J., Burry K.A., and Bethea C.L. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am J Obstet Gynecol 172 (1995) 1837 43 discussion 1843-4
164. van der Ven L.T., Gloudemans T., Roholl P.J., van Buul-Offers S.C., Bladergroen B.A., Welters M.J., et al. Growth advantage of human leiomyoma cells compared to normal smooth-muscle cells due to enhanced sensitivity toward insulin-like growth factor I. Int J Cancer 59 (1994) 427 34
165. Giudice L.C., Irwin J.C., Dsupin B.A., Pannier E.M., Jin I.H., Vu T.H., et al. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod 8 (1993) 1796 806
166. Yamada T., Nakago S., Kurachi O., Wang J., Takekida S., Matsuo H., et al. Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. Hum Reprod 19 (2004) 815 21
167. Palman C., Bowen-Pope D.F., and Brooks J.J. Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors. Lab Invest 66 (1992) 108 15
168. Arici A., and Sozen I. Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1 in human myometrium and leiomyoma. Am J Obstet Gynecol 188 (2003) 76-83
169. Fayed Y.M., Tsibris J.C., Langenberg P.W., and Robertson Jr. A.L. Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin. Lab Invest 60 (1989) 30 7
170. Ross R., Bowen-Pope D.F., and Raines E.W. Platelet-derived growth factor: its potential roles in wound healing, atherosclerosis, neoplasia, and growth and development. Ciba Found Symp 116 (1985) 98-112
171. Liang M., Wang H., Zhang Y., Lu S., and Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol Ther 5 (2006) 28-33
172. Boehm K.D., Daimon M., Gorodeski I.G., Sheean L.A., Utian W.H., and Ilan J. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev 27 (1990) 93-101
173. Mangrulkar R.S., Ono M., Ishikawa M., Takashima S., Klagsbrun M., and Nowak R.A. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol Reprod 53 (1995) 636 46
174. Hwu Y.M., Li S.H., Lee R.K., Tsai Y.H., Yeh T.S., and Lin S.Y. Increased expression of platelet-derived growth factor C messenger ribonucleic acid in uterine leiomyomata. Fertil Steril 89 (2008) 468 71
175. Ingman W.V., and Robertson S.A. Defining the actions of transforming growth factor beta in reproduction. Bioessays 24 (2002) 904 14
176. Verrecchia F., and Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol 13 (2007) 3056 62
177. Dou Q., Zhao Y., Tarnuzzer R.W., Rong H., Williams R.S., Schultz G.S., et al. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J Clin Endocrinol Metab 81 (1996) 3222 30
178. Tang X.M., Dou Q., Zhao Y., McLean F., Davis J., and Chegini N. The expression of transforming growth factor-beta s and TGF-beta receptor mRNA and protein and the effect of TGF-beta s on human myometrial smooth muscle cells in vitro. Mol Hum Reprod 3 (1997) 233 40
179. Chegini N., Tang X.M., and Ma C. Regulation of transforming growth factor-beta1 expression by granulocyte macrophage-colony-stimulating factor in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab 84 (1999) 4138 43
180. De Falco M., Staibano S., D'Armiento F.P., Mascolo M., Salvatore G., Busiello A., et al. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. J Soc Gynecol Investig 13 (2006) 297-303
181. Lee B.S., and Nowak R.A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 86 (2001) 913 20
182. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773 (2007) 1263 84
183. Barbarisi A., Petillo O., Di Lieto A., Melone M.A., Margarucci S., Cannas M., et al. 17-Beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J Cell Physiol 186 (2001) 414 24
184. Hermon T.L., Moore A.B., Yu L., Kissling G.E., Castora F.J., and Dixon D. Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. Virchows Arch 453 (2008) 557 69
185. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., and Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538 41
186. Carnevale R.P., Proietti C.J., Salatino M., Urtreger A., Peluffo G., Edwards D.P., et al. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol 21 (2007) 1335 58
187. Boonyaratanakornkit V., Scott M.P., Ribon V., Sherman L., Anderson S.M., Maller J.L., et al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 8 (2001) 269 80
188. Ballare C., Vallejo G., Vicent G.P., Saragueta P., and Beato M. Progesterone signaling in breast and endometrium. J Steroid Biochem Mol Biol 102 (2006) 2-10
189. Lengyel F., Vertes Z., Kovacs K.A., Kornyei J.L., Sumegi B., and Vertes M. Effect of estrogen and inhibition of phosphatidylinositol-3 kinase on Akt and FOXO1 in rat uterus. Steroids 72 (2007) 422 8
190. Vallejo G., Ballare C., Baranao J.L., Beato M., and Saragueta P. Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor beta induces proliferation of endometrial stromal cells. Mol Endocrinol 19 (2005) 3023 37
191. Hoekstra A.V., Sefton E.C., Berry E., Lu Z., Hardt J., Marsh E., et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab (2009) [in review]
192. Kovacs K.A., Lengyel F., Vertes Z., Kornyei J.L., Gocze P.M., Sumegi B., et al. Phosphorylation of PTEN (phosphatase and tensin homologue deleted on chromosome ten) protein is enhanced in human fibromyomatous uteri. J Steroid Biochem Mol Biol 103 (2007) 196 9
193. Bifulco G., Miele C., Pellicano M., Trencia A., Ferraioli M., Paturzo F., et al. Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. Mol Hum Reprod 10 (2004) 43 8
194. Hodges L.C., Houston K.D., Hunter D.S., Fuchs-Young R., Zhang Z., Wineker R.C., et al. Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells. Mol Cell Endocrinol 196 (2002) 11-20